Insulin-dependent diabetes mellitus (IDDM) is associated with antibodies to a 64,000-Mr islet cell protein, at least part of which is identified as glutamic acid decarboxylase (GAD). These antibodies are detected as two distinct antibody specificities to 50,000-Mr and 37,000/40,000-Mr tryptic fragments of the autoantigen (50K and 37K antibodies, respectively). We determined the frequencies of antibodies to intact GAD, tryptic fragments of islet 64,000-Mr antigen, islet cell antibodies (ICAs), and insulin autoantibodies (IAAs) in sera from 58 nondiabetic identical twins of patients with IDDM, of whom 12 subsequently developed diabetes. ICA, antibodies to intact GAD, and those to tryptic fragments were detected at similar frequencies in prediabetic twins (67–75%), but only 25% had IAA. Of 46 twins who remain nondiabetic, GAD antibodies, 50K antibodies, and ICA were detected in 6 (13%), 7 (15%), and 5 (11%), respectively, whereas only 1 (2%) possessed 37K antibodies and 2 (4%) had IAA. Eight of 9 twins with 37K antibodies and all 6 twins with ICA > 20 Juvenile Diabetes Foundation U have developed diabetes. Antibodies to GAD are sensitive markers for diabetes development but may also be present in genetically susceptible individuals who are unlikely to develop disease. Antibodies to 37,000/40,000-Mr fragments of the 64,000-Mr antigen or high-titer ICA were the best markers for diabetes development in these twins.
Skip Nav Destination
Article navigation
Original Articles|
July 01 1992
Antibodies to GAD and Tryptic Fragments of Islet 64K Antigen as Distinct Markers for Development of IDDM: Studies With Identical Twins
Michael R Christie;
Michael R Christie
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
Richard Y M Tun;
Richard Y M Tun
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
Simon S S Lo;
Simon S S Lo
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
David Cassidy;
David Cassidy
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
Thomas J Brown;
Thomas J Brown
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
Jacqueline Hollands;
Jacqueline Hollands
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
Marion Shattock;
Marion Shattock
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
Gian Franco Bottazzo;
Gian Franco Bottazzo
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
R David G Leslie
R David G Leslie
Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital
Oxford
Diabetic Research Unit, Charing Cross and Westminster Medical School
London
Department of Immunology, The London Hospital Medical College
London, United Kingdom
Search for other works by this author on:
Address correspondence and reprint requests to Dr. R.D.G. Leslie, Department of Diabetes, St. Bartholomew's Hospital, Dominion House, 59 Bartholomew Close, West Smithfield, London EC1A 7EE, UK.
Diabetes 1992;41(7):782–787
Article history
Received:
July 24 1991
Revision Received:
March 03 1992
Accepted:
March 03 1992
PubMed:
1612192
Citation
Michael R Christie, Richard Y M Tun, Simon S S Lo, David Cassidy, Thomas J Brown, Jacqueline Hollands, Marion Shattock, Gian Franco Bottazzo, R David G Leslie; Antibodies to GAD and Tryptic Fragments of Islet 64K Antigen as Distinct Markers for Development of IDDM: Studies With Identical Twins. Diabetes 1 July 1992; 41 (7): 782–787. https://doi.org/10.2337/diab.41.7.782
Download citation file:
44
Views